Multi-omics analysis links FERMT1 expression to patient survival, immunotherapy response, and metastasis across cancers | Synapse
March 3, 2026Open Access
Multi-omics analysis links FERMT1 expression to patient survival, immunotherapy response, and metastasis across cancers
Puntos clave
Fermt1 expression correlates with patient survival and tumor progression across multiple cancers, indicating its importance.
Key evidence shows that elevated Fermt1 levels are associated with improved immunotherapy response in lung adenocarcinoma.
The approach includes a multi-omics analysis, revealing insights into cancer biology and treatment implications across various cancer types.
This highlights the potential of Fermt1 as a therapeutic target, but further validation across diverse patient populations is needed.
Resumen
FERMT1 serves as a potential biomarker for LUAD prognosis and cancer immunotherapy, highlighting its role in tumor progression and therapeutic response.